DE3581921D1 - Synthetische polymere arzneistoffe. - Google Patents

Synthetische polymere arzneistoffe.

Info

Publication number
DE3581921D1
DE3581921D1 DE8585309560T DE3581921T DE3581921D1 DE 3581921 D1 DE3581921 D1 DE 3581921D1 DE 8585309560 T DE8585309560 T DE 8585309560T DE 3581921 T DE3581921 T DE 3581921T DE 3581921 D1 DE3581921 D1 DE 3581921D1
Authority
DE
Germany
Prior art keywords
peptide
mol
units derived
bound
methacryloylated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8585309560T
Other languages
English (en)
Inventor
Jindrich Kopecek
Pavla Rejmanova
Jiri Strohalm
Karel Ulbrich
Blanka Rihova
Vladimir Chytry
John B Lloyd
Ruth Duncan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Czech Academy of Sciences CAS
Cancer Research Campaign Technology Ltd
Original Assignee
Czech Academy of Sciences CAS
Cancer Research Campaign Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Czech Academy of Sciences CAS, Cancer Research Campaign Technology Ltd filed Critical Czech Academy of Sciences CAS
Application granted granted Critical
Publication of DE3581921D1 publication Critical patent/DE3581921D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/811—Peptides or proteins is immobilized on, or in, an inorganic carrier
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815—Carrier is a synthetic polymer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815—Carrier is a synthetic polymer
    • Y10S530/816—Attached to the carrier via a bridging agent
DE8585309560T 1985-01-04 1985-12-31 Synthetische polymere arzneistoffe. Expired - Lifetime DE3581921D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB858500209A GB8500209D0 (en) 1985-01-04 1985-01-04 Synthetic polymeric drugs

Publications (1)

Publication Number Publication Date
DE3581921D1 true DE3581921D1 (de) 1991-04-04

Family

ID=10572420

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8585309560T Expired - Lifetime DE3581921D1 (de) 1985-01-04 1985-12-31 Synthetische polymere arzneistoffe.

Country Status (9)

Country Link
US (1) US5037883A (de)
EP (1) EP0187547B1 (de)
JP (2) JPH075474B2 (de)
AT (1) ATE60991T1 (de)
AU (1) AU589587B2 (de)
CA (1) CA1305053C (de)
DE (1) DE3581921D1 (de)
DK (1) DK164485C (de)
GB (1) GB8500209D0 (de)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4738434A (en) 1986-04-07 1988-04-19 Marjoram Robert H Vibration and/or shock attenuating fluid mount or the like
JP2896580B2 (ja) * 1989-08-25 1999-05-31 チッソ株式会社 アミロース―リゾチームハイブリッドと活性化糖およびその製造法
EP0452179B1 (de) * 1990-03-28 1996-06-12 Nippon Oil And Fats Company, Limited Polymerkombiniertes Arzneimittel zur Magenbehandlung und Verfahren zu dessen Herstellung
CA2046830C (en) 1990-07-19 1999-12-14 Patrick P. Deluca Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
CZ2190U1 (cs) * 1991-02-01 1994-07-14 Alexandr Rndr. Csc. Jegorov Směrované polymerní konjugáty cyklosporinu
US5332575A (en) * 1991-10-03 1994-07-26 Parfums Christian Dior Method of targeting melanocytes with a compound containing a fucose residue
US5258453A (en) * 1992-01-21 1993-11-02 University Of Utah Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light
GB9213077D0 (en) * 1992-06-19 1992-08-05 Erba Carlo Spa Polymerbound taxol derivatives
GB2270920B (en) * 1992-09-25 1997-04-02 Univ Keele Alginate-bioactive agent conjugates
US7056935B2 (en) 1995-06-07 2006-06-06 Gpi Nil Holdings, Inc. Rotamase enzyme activity inhibitors
GB9600471D0 (en) * 1996-01-10 1996-03-13 Univ London Pharmacy Drug delivery system
GB9606975D0 (en) * 1996-04-02 1996-06-05 Univ Birmingham Anti-tumor agent
WO1997038727A1 (fr) * 1996-04-15 1997-10-23 Asahi Kasei Kogyo Kabushiki Kaisha Composite medicamenteux
US5965118A (en) * 1997-04-18 1999-10-12 Access Pharmaceuticals, Inc. Polymer-platinum compounds
AU7124598A (en) * 1997-04-18 1998-11-13 Access Pharmaceuticals, Inc. Polymer-platinum compounds
US6251866B1 (en) 1997-08-05 2001-06-26 Watson Laboratories, Inc. Conjugates targeted to the interleukin-2 receptor
US6180084B1 (en) * 1998-08-25 2001-01-30 The Burnham Institute NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same
US6066673A (en) * 1998-03-12 2000-05-23 The Procter & Gamble Company Enzyme inhibitors
US7018654B2 (en) 1999-03-05 2006-03-28 New River Pharmaceuticals Inc. Pharmaceutical composition containing an active agent in an amino acid copolymer structure
US7060708B2 (en) 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US6716452B1 (en) 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
AU1820400A (en) * 1999-11-17 2001-05-30 School Of Pharmacy, University Of London, The Conjugates of hpma copolymer and ellipticin
ATE281164T1 (de) 2000-02-24 2004-11-15 Kopran Res Lab Ltd Oral verabreichbare säurebeständige geschwürbehandelnde benzimidazolderivate
AU2001288829A1 (en) 2000-09-06 2002-03-22 Ap Pharma, Inc. Degradable polyacetal polymers
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
US20040234497A1 (en) * 2001-05-04 2004-11-25 Yi Luo Hyaluronic acid containing bioconjugates:targeted delivery of anti-cancer drugs to cancer cells
US7169752B2 (en) 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US20030124742A1 (en) * 2001-08-22 2003-07-03 Prakash Ramesh K. Conjugates targeted to target receptors
US7375082B2 (en) 2002-02-22 2008-05-20 Shire Llc Abuse-resistant hydrocodone compounds
US7338939B2 (en) 2003-09-30 2008-03-04 New River Pharmaceuticals Inc. Abuse-resistant hydrocodone compounds
US20060014697A1 (en) 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
CZ293787B6 (cs) * 2001-12-20 2004-07-14 Zentiva, A.S. pH senzitivní polymerní konjugáty antracyklinového kancerostatika pro cílenou terapii
US7105486B2 (en) 2002-02-22 2006-09-12 New River Pharmaceuticals Inc. Abuse-resistant amphetamine compounds
ES2500117T3 (es) 2002-02-22 2014-09-30 Shire Llc Novedosos compuestos farmacéuticos de liberación sostenida para prevenir el abuso de sustancias controladas
US7659253B2 (en) 2002-02-22 2010-02-09 Shire Llc Abuse-resistant amphetamine prodrugs
US7700561B2 (en) 2002-02-22 2010-04-20 Shire Llc Abuse-resistant amphetamine prodrugs
AU2003226349B2 (en) * 2002-04-11 2008-01-31 Children's Medical Center Corporation Methods for inhibiting vascular hyperpermeability
EP1494662B1 (de) * 2002-04-11 2012-11-28 Children's Medical Center Corporation Tnp-470-hpma-methacrylsäure kopolymer-konjugate und ihre verwendung
CA2483696A1 (en) * 2002-05-06 2003-11-20 University Of Utah Research Foundation Preblocking with non-ha gags increases effectiveness of ha conjugated anticancer agents
US20040116348A1 (en) * 2002-09-23 2004-06-17 Ying Chau Polymer-linker-drug conjugates for targeted drug delivery
US8133881B2 (en) 2003-01-13 2012-03-13 Shire Llc Carbohydrate conjugates to prevent abuse of controlled substances
JP4757633B2 (ja) * 2003-03-20 2011-08-24 日本化薬株式会社 難水溶性抗癌剤と新規ブロック共重合体を含むミセル調製物
ES2340494T3 (es) 2003-04-15 2010-06-04 Glaxosmithkline Llc Mutantes de sustitucion de il-18 humana y sus conjugados.
DK1644019T4 (en) 2003-05-29 2018-04-23 Shire Llc AMPHETAMINE COMPOUNDS RESISTANT TO ABUSE
SG147485A1 (en) 2003-09-30 2008-11-28 Shire Llc Pharmaceutical compositions for prevention of overdose or abuse
ZA200603619B (en) * 2003-11-06 2008-10-29 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
ES2641570T3 (es) * 2004-03-31 2017-11-10 University Of Utah Research Foundation Sistemas de suministro macromoleculares para imagenología no invasiva, evaluación y tratamiento de artritis y otras enfermedades inflamatorias
US20080113028A1 (en) * 2004-09-22 2008-05-15 Kazuhisa Shimizu Novel Block Copolymer, Micelle Preparation, And Anticancer Agent Containing The Same As Active Ingredient
EP1835888B1 (de) 2005-01-14 2017-07-12 Korea Institute of Science and Technology Selbstaggregate bildender cholansäure-chitosan-komplex und herstellungsverfahren
US20080248030A1 (en) * 2005-02-02 2008-10-09 Children's Medical Center Corporation Method of Treating Angiogenic Diseases
KR20080106254A (ko) 2006-03-28 2008-12-04 니폰 가야꾸 가부시끼가이샤 탁산류의 고분자 결합체
EP2019122A4 (de) 2006-05-18 2009-07-01 Nippon Kayaku Kk Polymerkonjugat von podophyllotoxin
WO2007143209A2 (en) * 2006-06-02 2007-12-13 University Of Virginia Patent Foundation Luminescent diketonate polymers
WO2008041610A1 (fr) * 2006-10-03 2008-04-10 Nippon Kayaku Kabushiki Kaisha Mélange d'un dérivé de résorcinol avec un polymère
WO2008056596A1 (en) 2006-11-06 2008-05-15 Nippon Kayaku Kabushiki Kaisha Polymeric derivative of nucleic acid metabolic antagonist
JP5548365B2 (ja) 2006-11-08 2014-07-16 日本化薬株式会社 核酸系代謝拮抗剤の高分子誘導体
CN1973902B (zh) * 2006-12-12 2010-11-10 东北师范大学 以人参多糖为载体的抗肿瘤药物阿霉素复合物及制备方法
JP5349318B2 (ja) 2007-09-28 2013-11-20 日本化薬株式会社 ステロイド類の高分子結合体
CN101977631A (zh) * 2008-03-18 2011-02-16 日本化药株式会社 生理活性物质的高分子量偶联物
EP2284209B1 (de) 2008-05-08 2016-08-31 Nippon Kayaku Kabushiki Kaisha Polymerkonjugat aus folsäure oder einem folsäurederivat
MX2011003738A (es) * 2008-10-07 2011-09-30 Rexahn Pharmaceuticals Inc Conjugados hpma-docetaxel o gemcitabine y sus usos asociados.
JP5544357B2 (ja) 2009-05-15 2014-07-09 日本化薬株式会社 水酸基を有する生理活性物質の高分子結合体
KR20150058554A (ko) 2009-10-13 2015-05-28 렉산 파마슈티컬스, 인코포레이티드 항암제의 전달을 위한 폴리머 시스템
CZ302830B6 (cs) * 2009-12-15 2011-11-30 Ústav makromolekulární chemie AV CR, v.v.i. Vysokomolekulární polymerní nosice léciv odvozené od dendrimeru a jejich konjugáty s lécivy pro lécbu zejména pevných nádoru
US9289510B2 (en) 2010-03-08 2016-03-22 University Of Utah Research Foundation Polymeric drug delivery conjugates and methods of making and using thereof
US9320805B2 (en) 2010-05-25 2016-04-26 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
US9895449B2 (en) 2010-05-25 2018-02-20 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
WO2012067138A1 (ja) 2010-11-17 2012-05-24 日本化薬株式会社 新規なシチジン系代謝拮抗剤の高分子誘導体
MX353301B (es) 2011-02-11 2018-01-08 The Regents The Univ Of Michigan Composiciones tripeptidicas y metodos para tratamiento de diabetes.
WO2013035641A1 (ja) 2011-09-11 2013-03-14 日本化薬株式会社 ブロック共重合体の製造方法
US10251906B2 (en) 2013-03-12 2019-04-09 University Of Utah Research Foundation Compositions and methods for inducing apoptosis
CN105431426A (zh) 2013-04-10 2016-03-23 新德发制药有限公司 Metap2抑制剂和治疗肥胖症的方法
CN103965398B (zh) * 2014-04-11 2016-04-13 西北师范大学 D-半乳糖/苯甲醛氮芥/n-(2-羟丙基)甲基丙烯酰胺共聚物及其制备和应用
US9969722B2 (en) 2015-12-10 2018-05-15 Syndevrx, Inc. Fumagillol derivatives and polymorphs thereof
CA3008960A1 (en) 2016-01-11 2017-07-20 Syndevrx, Inc. Treatment for tumors driven by metabolic dysfunction
US11879019B2 (en) 2016-12-19 2024-01-23 The Regents Of The University Of California Dual-enzyme responsive peptides
EP3554548A4 (de) 2016-12-19 2020-08-19 The Regents of The University of California Nicht brechbare tablettenformulierungen
BR112019021742A2 (pt) 2017-04-17 2020-05-05 Univ Chicago composição, sistema, composição farmacêutica, composição alimentícia ou nutracêutica, método e uso da composição
US10894019B2 (en) 2017-08-15 2021-01-19 University Of South Carolina Drug delivery system and method for targeting cancer stem cells
CA3117666A1 (en) 2018-10-26 2020-04-30 Syndevrx, Inc. Biomarkers of metap2 inhibitors and applications thereof
US11672767B2 (en) 2019-05-13 2023-06-13 University Of South Carolina Enzymatically cleavable self-assembled nanoparticles for morphogen delivery

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL133221C (de) * 1965-11-12
US3957700A (en) * 1972-05-04 1976-05-18 British Industrial Plastics Limited Filled aminoplast moulding materials
US4007142A (en) * 1974-04-24 1977-02-08 Balm Paints Limited Amine resin and process
GB8311136D0 (en) * 1983-04-25 1983-06-02 Lepetit Spa Immobilised oligopeptides

Also Published As

Publication number Publication date
US5037883A (en) 1991-08-06
ATE60991T1 (de) 1991-03-15
EP0187547A2 (de) 1986-07-16
DK3386A (da) 1986-07-05
JPS61243026A (ja) 1986-10-29
CA1305053C (en) 1992-07-14
EP0187547A3 (en) 1987-07-22
DK164485C (da) 1992-11-23
JPH075474B2 (ja) 1995-01-25
DK3386D0 (da) 1986-01-03
AU589587B2 (en) 1989-10-19
DK164485B (da) 1992-07-06
JP2620517B2 (ja) 1997-06-18
EP0187547B1 (de) 1991-02-27
GB8500209D0 (en) 1985-02-13
JPH07300428A (ja) 1995-11-14
AU5183386A (en) 1986-07-10

Similar Documents

Publication Publication Date Title
DE3581921D1 (de) Synthetische polymere arzneistoffe.
WO1997025067A3 (en) Polymers
DE69431185D1 (de) Erweiterung des vitamin b 12 - aufnahmesystems unter verwendung von polymeren
BR9713486A (pt) Preparações farmacêuticas compreendidas de sais de ácido hialurÈnico com anestésicosm locais.
PT88703A (pt) Die erfindung betriffte ein implantierbares biologisch abbaubares wirkstoffreigabesystem
DE3650753D1 (de) Auf einmaligen sequenzen innerhalb des veränderlichen gebiets des t-zellrezeptors basierte diagnosemittel und deren verwendung
AR014940A1 (es) Un portador para la liberacion de un agente bioactivo, un polimero poliester biodegradable, copolimeros y composiciones farmaceuticas que loscontienen.
DE69027950T2 (de) Auf Polyurethan basierende Polymermaterialien und diese verwendende biomedizinische Artikel und pharmazeutische Zusammensetzungen
EP1518550A3 (de) Bioadhäsive Darreichungssysteme mit Poly(fumarsäure-co-sebacinsäure)
ATE256182T1 (de) Neuartiges p- selectin ligandenprotein
DE69017180D1 (de) Biologisch wirksame polymere arzneistoffderivate.
DE60018564D1 (de) Funktionsfähige poly-alpha-aminosäurederivate zur modifizierung von biologisch wirksamen stoffen und deren herstellung
IT1249045B (it) Processo per la sintesi allo stato solido di polimeri dell'acido lattico e prodotti cosi ottenuti
DK0998501T3 (da) Kationiske polymerer, komplekser, som associerer de kationiske polymerer og terapeutisk aktive substanser, der omfatter mindst én negativ ladning, især nukleinsyrer, og anvendelse i genterapi
PT83241B (pt) Processo para a preparacao de composicoes de drogas de matriz polimerica, capazes de mascarar o sabor de um ingrediente activo, contendo um polimero tendo uma serie de grupos acido e ester carboxilicos
ES2052554T3 (es) Poliaminas polimeras.
DE3687238T2 (de) Polyamidharze.
ITMI911950A1 (it) Sistema terapeutico transdermale per la somministrazione di farmaci ad attivita' broncodilatante.
FI962985A (fi) Oraalinen lääkemuoto, jossa on happamia vaikuttavia aineita, ja menetelmä sen valmistamiseksi
GB2324534A (en) Polymers
DE68909451D1 (de) Peptide mit inhibitorischer wirkung auf enzymatische systeme, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
SCHOTMAN Reaction of isocyanates with carboxylic acids and its application to polymer synthesis(Ph. D. Thesis)
TH2661EX (th) น้ำยาดัดผมสำหรับดัดโดยใช้ความร้อนและกรรมวิธีในการดัดผม
ATE75485T1 (de) Biologisch aktive peptide, deren verfahren zur herstellung und pharmazeutische zusammensetzungen.
TH19871A (th) ซับสทิทิวเทดเบนแซมิดีน การเตรียมและการใช้สารเหล่านี้เป็นสารเภสัชกรรม

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee